ArticleVeterinary world2025
Antidiabetic, hypolipidemic, and antioxidative properties of aqueous and ethanolic extracts of Sage (
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Diabetes mellitus (DM) is a chronic disease characterized by insulin insufficiency and hyperglycemia, often leading to complications such as oxidative stress, dyslipidemia, and organs damage. Sage ( Materials and Methods: Wistar albino male rats (n = 49) were divided into seven groups: Normal control, diabetes-induced control (STZ), metformin-treated (50 mg/kg/day), and groups treated with AE (400 and 800 mg/kg/day) and EE (400 and 800 mg/kg/day). Parameters assessed included weight gain percentage, random blood glucose (RBG), fasting blood glucose (FBG), lipid profiles, liver and kidney function markers, oxidative stress biomarkers (glutathione [GSH], catalase [CAT], superoxide dismutase [SOD], malonaldehyde [MDA]), and histopathological examination of the pancreas. Results: AE and EE significantly reduced RBG and FBG and improved weight gain recovery. At 800 mg/kg, AE and EE effectively reduced triglycerides, total cholesterol, low-density lipoproteins cholesterol (LDL-C), and very LDL-C (VLDL-C) while increasing high-density lipoproteins cholesterol more than 400 mg/kg doses or metformin. Liver and kidney functions were restored with high-dose AE and EE showing superior efficacy. Antioxidant biomarkers (GSH, CAT, and SOD) were significantly enhanced, while MDA levels were reduced. Histopathological analysis confirmed restoration of islets of Langerhans and acinar cells to near-normal conditions in treated groups. Conclusion: The AE and EE of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.